NAMSA celebrates 50 years of scientific innovation in the medtech industry

NAMSA, the world’s only Medical Research Organization (MRO) that accelerates medical device development through integrated laboratory, clinical and consulting services, will celebrate its 50th anniversary on June 29. NAMSA, founded in 1967, was the first independent company in the world to focus solely on testing medical devices and materials. Established nearly 10 years before the

NAMSA announces partnership with Naglreiter

Medical research organization NAMSA today announced a partnership with the Naglreiter medical device development organization, which focuses on medical device design, development and manufacturing. For nearly 50 years, NAMSA has focused on offering the most critical services required to accelerate time-to-market and reduce costs for medical device research clients across the world. Consistently recognized as a pioneer in

Wading into parallel reviews as a reimbursement strategy

The process of gaining reimbursement is one of the most expensive and perilous activities a medical technology company will undergo. Some are exploring how (and whether) a strategy that encourages working with both FDA and CMS at the same time can help cut down the resource costs associated with reimbursement. Seth Goldenberg, director of product

Why regional reimbursement strategies could be right for medtech

The medtech space is facing increasing challenges, particularly in the reimbursement space. Although the process is difficult, device makers may find that regional reimbursement strategies better suit their immediate needs to get products to market, according to experts at NAMSA. Let’s start with the challenges. We know that clinical trials for devices are far more

NAMSA expands service offering in China with opening of Shanghai laboratory

NAMSA, the world’s only Medical Research Organization (MRO), is pleased to announce the opening of its state-of-the-art preclinical medical device research laboratory in Shanghai, China. This opening represents the organization’s third Asian-Pacific location and NAMSA’s growing investment in Chinese-based lab services and commitment to assisting clients in efficiently bringing products to the global marketplace. The

NAMSA expands service offering in China with opening of Shanghai laboratory

NAMSA, the world’s only Medical Research Organization (MRO), is pleased to announce the opening of its state-of-the-art preclinical medical device research laboratory in Shanghai, China. This opening represents the organization’s third Asian-Pacific location and NAMSA’s growing investment in Chinese-based lab services and commitment to assisting clients in efficiently bringing products to the global marketplace. The

NAMSA expands service offering expertise into South America

NAMSA, a medical research organization is pleased to announce the addition of Blanchard & Associates as NAMSA’s local agent in South America. Blanchard & Associates is a clinical research organization (CRO) with extensive clinical study experience executed for clients throughout Latin America. Blanchard & Associates offers services including; clinical research, preclinical testing expertise, regulatory and quality

NAMSA and Fortuna Clinical form strategic relationship

NAMSA, a global medical research organization, and Fortuna Clinical, a global medical device clinical research organization, are pleased to announce their strategic relationship. As a result of the increase in demand of NAMSA’s clinical services driven by the development of the MRO Approach, NAMSA and Fortuna Clinical have engaged in a strategic partnership to expand their